false
English
Catalog
2023 World Conference on Lung Cancer (Posters)
EP07.02. Impact of Neoadjuvant Immunotherapy on Su ...
EP07.02. Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer:A Multi-center Survey of Current Practice from China - PDF(Slides)
Back to course
Pdf Summary
A survey was conducted in China to investigate the impact of neoadjuvant immunotherapy on surgical practice for non-small cell lung cancer (NSCLC). The survey included 267 responses from thoracic surgeons across 27 provinces. The majority of surgeons had more than 10 years of experience and worked in high-volume centers.<br /><br />The most common setting for neoadjuvant immunotherapy was central NSCLC of stage III. Surgeons considered tumor size, lymph node metastasis, and probability of R0 resection when deciding on neoadjuvant immunotherapy. Surgery was typically performed 4-6 weeks after the completion of immunotherapy, with lobectomy being the most common type of surgery.<br /><br />Surgeons reported observing immune-related adverse events in 45% of cases, and this was more common in experienced surgeons. There were variations in opinions regarding the difficulty of surgery after neoadjuvant immunotherapy, with 32% of surgeons reporting increased difficulty, 32% reporting comparable difficulty, and 29% believing that the difficult cases became harder and the easy cases became easier. However, most surgeons agreed that neoadjuvant immunotherapy did not increase the risk of intraoperative or postoperative major adverse events.<br /><br />Overall, neoadjuvant immunotherapy was found to result in acceptable adverse events, enhance resectability, and not increase the complexity of surgery for most experienced surgeons. The findings of this survey highlight the variations in surgical management preferences among thoracic surgeons in China.
Asset Subtitle
Han Wu
Meta Tag
Speaker
Han Wu
Topic
Early-Stage NSCLC: New Technology & Innovations
Keywords
neoadjuvant immunotherapy
surgical practice
NSCLC
survey
thoracic surgeons
tumor size
lymph node metastasis
lobectomy
adverse events
surgical management
×
Please select your language
1
English
5
普通话
11
Dutch